Effects of octreotide on central hemodynamics and systemic oxygen use in patients with viral cirrhosis.
OBJECTIVE
Octreotide has potentially beneficial effects in patients with cirrhosis. However, the effects of octreotide on central hemodynamics and oxygen use have not been established. The present study was undertaken to evaluate the effect of octreotide on central hemodynamics and oxygen use in patients with viral cirrhosis.


METHODS
Twenty-five patients with cirrhosis were enrolled in the study. They were randomly assigned to receive either placebo (n = 10) or a continuous infusion of 100 microg/h of octreotide after an initial 100-microg bolus (n = 15). Hemodynamic measurements and oxygenation values were obtained before and 60 min after octreotide or placebo administration.


RESULTS
Placebo administration did not have any effect on hemodynamic and oxygenation values. In patients who received octreotide, systemic hemodynamic values including cardiac index, mean arterial pressure, and systemic vascular resistance were not affected. The mean pulmonary arterial pressure tended to increase after octreotide administration but was statistically insignificant. There was a significant increase in pulmonary arterial vascular resistance, whereas the pulmonary capillary wedge pressure and right atrial pressure were significantly decreased. Arterial oxygen tension, systemic oxygen uptake, and oxygen extraction ratio were significantly decreased after octreotide administration, whereas oxygen transport as well as arterial and mixed venous oxygen contents remained unchanged.


CONCLUSIONS
In patients with viral cirrhosis, octreotide administration exerted a significant effect on pulmonary circulation. It also resulted in a decrease in systemic oxygen uptake and oxygen extraction ratio. These results suggested that octreotide may impair tissue oxygenation in patients with viral cirrhosis.
Lin
H C
HC
Department of Medicine, Taipei Veterans General Hospital and National Yang-Ming University School of Medicine, Taiwan, ROC.
Hou
M C
MC
Lee
W C
WC
Huang
Y T
YT
Lee
F Y
FY
Chang
F Y
FY
Tsai
Y T
YT
Lee
S D
SD
D000368:Aged; D006439:Hemodynamics / Q000187:drug effects*; D006509:Hepatitis B / Q000150:complications; D006526:Hepatitis C / Q000150:complications; D006728:Hormones / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007262:Infusions, Intravenous; D008103:Liver Cirrhosis / Q000188:drug therapy / Q000503:physiopathology / Q000821:virology*; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000008:administration & dosage / Q000627:therapeutic use*; D010101:Oxygen Consumption / Q000187:drug effects*; D011652:Pulmonary Circulation / Q000187:drug effects
D006728:Hormones; D015282:Octreotide